Haemophilia Treatment in India: Symptoms, Causes, Types, Diagnosis & Advanced Care

By: Dr. Sunil Udgire
Consultant Haematologist, Paediatric Oncologist and BMT Physician
Posted on May 25, 2025

Haemophilia Treatment in India: Symptoms, Causes, Types, Diagnosis & Advanced Care

Haemophilia is a rare genetic disorder that affects the blood’s ability to clot. When a person is injured, proteins called clotting factors work together to stop bleeding. In people with haemophilia, one of these clotting factors is either missing or present at very low levels, leading to prolonged and sometimes life-threatening bleeding episodes. As a leading destination for rare blood disorder treatment, India offers world-class care for haemophilia patients from across the globe.

This condition is typically inherited, meaning it is passed down through families. However, it can also occur due to a spontaneous genetic mutation. Haemophilia primarily affects males, though females can be carriers and sometimes experience mild symptoms. With advances in haemophilia treatment in India, including clotting factor replacement therapy, gene therapy, and comprehensive supportive care, patients today can live healthy, active lives.

In this blog, we define haemophilia, explore its causes, recognise key haemophilia symptoms, understand the different types, and outline haemophilia diagnosis and treatment pathways, including information on haemophilia treatment cost in India for domestic and international patients.

What is Haemophilia?

Haemophilia is a genetic disorder in which the body either lacks or has dangerously low levels of specific blood clotting factors. Normally, when a person is injured, a cascade of proteins — including Factor VIII, Factor IX, and Factor XI, work in sequence to form a stable blood clot and stop bleeding. In haemophilia, a defect in one of these factors disrupts the cascade, resulting in prolonged or spontaneous bleeding.

Haemophilia primarily affects males due to its X-linked inheritance pattern, though carrier females may also experience mild haemophilia symptoms. It is classified as a rare blood disorder, affecting approximately 1 in 5,000 male births worldwide. Seeking care at the best hospital for haemophilia in India is essential for accurate haemophilia diagnosis, personalised treatment, and long-term monitoring.

Haemophilia Symptoms

The severity of haemophilia symptoms depends on the amount of clotting factor present in the blood. Symptoms may appear in infancy or emerge later in life, depending on the degree of deficiency.

Common haemophilia symptoms include:

  • Heavy or prolonged bleeding from cuts, injuries, dental procedures, or surgeries
  • Frequent and unexplained nosebleeds
  • Easy bruising with minor trauma
  • Blood in urine (haematuria) or stool (melaena)
  • Swollen, painful, and warm joints due to haemarthrosis (internal joint bleeding)
  • Excessive bleeding following vaccinations or routine injections
  • Prolonged bleeding after childbirth or surgical procedures
  • In severe cases: spontaneous internal bleeding into muscles and organs without any trauma

Recognising these haemophilia symptoms early and consulting a specialist promptly is critical. Delayed haemophilia diagnosis can lead to irreversible joint damage, chronic pain, and other serious complications. If you or a family member display these signs, consult a haematologist at the best hospital for haemophilia in India immediately.

Haemophilia Causes

Haemophilia is caused by a mutation in a gene located on the X chromosome, which disrupts the production of essential clotting factors. Since males carry only one X chromosome (XY), a single defective copy means they will have the condition. Females (XX) typically carry the trait on one X chromosome and are usually unaffected, though carrier females can pass the gene to their children and occasionally exhibit mild symptoms if both X chromosomes are affected.

Not all cases are inherited. Approximately 30% of haemophilia cases arise from spontaneous de novo mutations with no prior family history. There is also a rare form known as acquired haemophilia, which develops in adulthood when the immune system mistakenly produces antibodies, called inhibitors, that attack the body’s own clotting factors. This can occur in association with autoimmune conditions, malignancies, or during pregnancy.

Types of Haemophilia

There are three primary types of haemophilia, each distinguished by which clotting factor is deficient:

1. Haemophilia A (Classic Haemophilia)

The most common type, Haemophilia A is caused by a deficiency of Factor VIII. It accounts for approximately 80% of all haemophilia cases. The severity ranges from mild to severe based on Factor VIII levels in the blood. Severe Haemophilia A is characterised by spontaneous bleeding into joints and muscles. Factor VIII deficiency treatment for international patients seeking care in India is available at specialised haemophilia treatment centres with access to plasma-derived and recombinant Factor VIII concentrates.

2. Haemophilia B (Christmas Disease)

Haemophilia B is caused by a deficiency of Factor IX. It is less common than Haemophilia A but presents with similar haemophilia symptoms, prolonged bleeding, joint bleeds, and easy bruising. It is named after Stephen Christmas, the first patient in whom the condition was described. Clotting factor replacement therapy with Factor IX concentrate is the cornerstone of management, and gene therapy for Haemophilia B has shown particularly promising results in recent clinical trials.

3. Haemophilia C

Caused by a deficiency of Factor XI, Haemophilia C is very rare and generally milder in presentation. It most commonly affects people of Ashkenazi Jewish descent. Unlike Haemophilia A and B, bleeding in Haemophilia C does not always correlate with Factor XI levels and more commonly occurs after trauma or surgery rather than spontaneously.

Haemophilia Diagnosis

Early and accurate haemophilia diagnosis is crucial for effective disease management and prevention of complications. Haemophilia diagnosis typically involves the following steps:

  • Complete Blood Count (CBC) and blood tests to measure clotting time (Prothrombin Time and Activated Partial Thromboplastin Time)
  • Specific clotting factor assays to measure Factor VIII, IX, or XI activity levels and determine disease severity (mild, moderate, or severe)
  • Inhibitor testing to check if the patient has developed antibodies against clotting factors
  • Genetic testing to identify the specific gene mutation, confirm the diagnosis, and counsel carrier females
  • Prenatal diagnosis for at-risk families through chorionic villus sampling or amniocentesis

Physicians may suspect haemophilia in newborns with unexpected bleeding after circumcision, in infants with unexplained bruising, or in toddlers who bruise excessively when they begin walking. A complete haemophilia diagnosis requires specialised laboratory facilities and a multidisciplinary team of haematologists, genetic counsellors, and physiotherapists, all available at the best hospital for haemophilia in India.

Haemophilia Treatment in India

Haemophilia treatment in India has evolved significantly over the past decade. Leading haematology centres now offer the full spectrum of evidence-based therapies, from clotting factor replacement therapy to cutting-edge gene therapy. The goal of treatment is to prevent and control bleeding episodes, protect joints from long-term damage, and improve patients’ quality of life.

1. Clotting Factor Replacement Therapy

Clotting factor replacement therapy remains the gold standard for haemophilia treatment in India and globally. Missing clotting factors are administered intravenously in two main protocols:

  • Prophylactic Treatment: Regular infusions of Factor VIII (for Haemophilia A) or Factor IX (for Haemophilia B) are given two to three times per week, even in the absence of active bleeding. This preventive approach significantly reduces joint bleeding, long-term joint damage, and hospitalisations. It is strongly recommended for children and patients with severe disease.
  • On-Demand (Episodic) Treatment: Clotting factor infusions are given only when a bleed occurs. This approach is appropriate for patients with milder forms of haemophilia or in resource-limited settings. Extended half-life clotting factor products, now available in India, allow for less frequent infusions and improved adherence.

2. Non-Replacement Therapies

A new class of therapies has transformed haemophilia treatment in India for patients who develop inhibitors or require alternative approaches:

  • Emicizumab (Hemlibra): A bispecific antibody that mimics the function of Factor VIII, administered subcutaneously once weekly, fortnightly, or monthly. It is approved for both Haemophilia A with and without inhibitors, and has dramatically reduced bleed rates in clinical trials.
  • Desmopressin (DDAVP): A synthetic hormone that stimulates the release of stored Factor VIII in patients with mild Haemophilia A, reducing the need for clotting factor concentrates.
  • Antifibrinolytics: Medicines such as tranexamic acid help stabilise blood clots and are useful as adjuncts during dental procedures, surgery, or minor bleeds.

3. Gene Therapy

Gene therapy represents the most exciting frontier in haemophilia treatment in India and worldwide. It aims to provide a long-term or permanent solution by introducing a functional copy of the defective clotting factor gene into the patient’s cells, enabling the body to produce its own clotting factor. Several gene therapy products have received regulatory approval or are in advanced clinical trials:

  • Fitusiran: An RNA interference therapy that targets antithrombin to reduce bleeding in haemophilia with or without inhibitors.
  • Valoctocogene Roxaparvovec (Roctavian): Approved for severe Haemophilia A, delivering a functional Factor VIII gene via an adeno-associated virus (AAV) vector.
  • Etranacogene Dezaparvovec (Hemgenix): Approved for Haemophilia B, offering durable Factor IX production with a single infusion.

Gene therapy is currently offered at select top-tier haematology centres in India for eligible patients. Early evidence suggests that gene therapy can raise clotting factor levels into the mild or even normal range, substantially reducing bleeding episodes and improving quality of life. It is particularly transformative for Factor VIII deficiency treatment for international patients seeking care in India.

4. Management of Inhibitors

Approximately 20–30% of patients with severe Haemophilia A and 1–5% of those with Haemophilia B develop inhibitors, antibodies that neutralise clotting factors and significantly complicate treatment. Management includes:

  • Immune Tolerance Induction (ITI): High-dose clotting factor infusions given daily over months to years to suppress inhibitors
  • Bypassing agents such as activated prothrombin complex concentrates (aPCC) or recombinant Factor VIIa to control bleeds in the presence of inhibitors
  • Emicizumab as a prophylactic option for patients with inhibitors

5. Bone Marrow Transplant for Blood Disorders

While bone marrow transplant for blood disorders is not a routine treatment for haemophilia, it has been explored as a potential curative option in select cases, particularly in patients with severe haemophilia and inhibitors who do not respond to standard therapies. Haematopoietic stem cell transplantation (HSCT) combined with gene editing technologies is an active area of research. Leading bone marrow transplant for blood disorders centres in India, such as those in Bangalore, offer specialised evaluation for patients who may be candidates for these experimental approaches.

6. Supportive Care and Physiotherapy

Supportive treatments are integral to comprehensive haemophilia care:

  • Physical therapy and hydrotherapy to maintain joint flexibility, strengthen muscles, and prevent long-term disability
  • Orthopaedic evaluation and, where necessary, joint replacement surgery for severe arthropathy
  • Pain management using paracetamol or COX-2 inhibitors (avoiding NSAIDs and aspirin, which impair platelet function)
  • Dental hygiene and preventive dental care to minimise the need for invasive dental procedures

7. Lifestyle Modifications

In addition to medical therapies, the following lifestyle adaptations reduce bleeding risk:

  • Prefer low-impact activities: swimming, walking, and cycling over high-contact sports
  • Use protective gear: helmets, knee pads, elbow guards, and seat belts during daily activities
  • Maintain a healthy weight to reduce strain on joints and decrease bleeding risk
  • Follow a balanced diet rich in calcium and vitamin D to support bone health
  • Avoid medications that impair clotting, including aspirin, ibuprofen, and other NSAIDs

Haemophilia Treatment Cost in India

One of the key reasons patients from South Asia, the Middle East, Africa, and beyond seek care in India is the significantly lower haemophilia treatment cost in India compared to Western countries, without compromise in quality. The haemophilia treatment cost in India varies depending on the type of haemophilia, disease severity, chosen treatment modality, hospital, and city of treatment. To get an estimate, contact SPARSH Hospitals – Global Care.

Factor VIII Deficiency Treatment for International Patients in India

India has become a preferred global destination for affordable healthcare for Factor VIII deficiency treatment for international patients due to its combination of highly trained haematologists, state-of-the-art infrastructure, affordable haemophilia treatment cost in India, and English-speaking medical teams. Key advantages include:

  • Access to both plasma-derived and recombinant Factor VIII and Factor IX concentrates
  • Availability of extended half-life products and novel non-replacement therapies
  • Participation in international gene therapy trials
  • Dedicated international patient services with visa facilitation, accommodation support, and telemedicine follow-up
  • Centres accredited by the National Accreditation Board for Hospitals (NABH) and Joint Commission International (JCI)

Whether you are seeking routine prophylactic care or advanced interventions like gene therapy or bone marrow transplant for blood disorders, the best hospital for haemophilia in India can provide comprehensive, cost-effective, and compassionate care.

Living with Haemophilia

Living with haemophilia requires ongoing lifestyle adaptations, vigilant preventive care, and a strong support network:

  • Avoid contact sports and high-risk activities to prevent injury
  • Carry a medical identification card or bracelet clearly stating your diagnosis, clotting factor deficiency type, and emergency treatment protocol
  • Educate teachers, employers, friends, and family members about recognising bleeding episodes and administering first aid
  • Attend regular comprehensive care clinic appointments, including joint evaluations, inhibitor testing, and psychological support
  • Home infusion programmes allow patients to self-administer clotting factor concentrates, significantly reducing hospital visits and improving quality of life
  • Women of childbearing age should consult a genetic counsellor and a specialist haematologist to discuss inheritance risks, prenatal testing options, and safe delivery planning

With appropriate haemophilia treatment in India and self-management education, most people with haemophilia can pursue education, employment, and an active lifestyle with minimal limitations.

Conclusion

Haemophilia is a lifelong but manageable condition. With early haemophilia diagnosis, access to clotting factor replacement therapy, emerging gene therapy, and comprehensive supportive care, individuals with haemophilia today enjoy far better outcomes than previous generations. India, with its rapidly advancing haematology infrastructure, offers some of the most effective and affordable rare blood disorder treatment options in the world.

If you or a loved one needs specialised care, consult the best Bone Marrow Transplant doctors in Bangalore and consider the best Bone Marrow Transplant hospital in Bangalore to ensure access to the latest therapies and experienced medical teams.